The contemporary psychiatric and neuropharmacological landscape across the United Kingdom, Germany, Sweden, New Zealand, Dubai, Australia, and the Netherlands is undergoing a profound structural evolution regarding the clinical re-evaluation of empathogenic and entactogenic compounds. As clinical investigators, public health authorities, and academic scholars evaluate innovative therapeutic models for treatment-resistant psychological conditions, researchers increasingly analyze substances […]